Antitumor and adjuvant effects of phagelysates of E.coli in mice with Ehrlich carcinoma

Experimental Oncology

Volumn 34, Issue 2, 2012, Pages 107-111

  Gambashidze, K ^a   Khorava, P ^a   Azaladze, T ^a   Kalandarishvili, K ^a   Jaiani, E ^b   Lasareishvil, B ^a,b   Azaladze, A ^a   Tediashvili, M ^b  

^a TBILISI STATE MEDICAL UNIVERSITY   (Georgia)

^b George Eliava Institute of Bacteriophage Microbiology and Virology   (Georgia)

Author keywords

Cancer; Chemotherapy; E. Coli; Immunotherapy; Phagelysates

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; NATURAL PRODUCT; PHAGELYSATE DERIVATIVE; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIOPHAGE; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; EHRLICH ASCITES TUMOR; ESCHERICHIA COLI; IMMUNOSUPPRESSIVE TREATMENT; LIFESPAN; MALE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; TUMOR XENOGRAFT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIOPHAGES; CARCINOMA, EHRLICH TUMOR; CELL EXTRACTS; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; ESCHERICHIA COLI; MALE; MICE; MICE, INBRED C57BL; SURVIVAL ANALYSIS;

EID: 84865989482     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Canaparo R, Casale F, Muntoni E. Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Br J Clin Pharmacol 2000; 50: 146-53. (Pubitemid 30612032)
2. Pivot X, Guardiola E, Etienne M. An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia. Eur J Cancer 2000; 36: 852-57. (Pubitemid 30214134)
3. de Visser K, Eichten A, Coussens L. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37. (Pubitemid 43053650)
4. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454: 436-44.
5. Lewis C, Pollard J. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-12. (Pubitemid 43165918)
6. Steiner H, Bonsanto M, Beckhove P, et al. Antitumor vaccination of patients with glioblastoma multiforme: A pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 2004; 22: 4272-81. (Pubitemid 41185148)
7. Moskaleva E, Ceverin C. Perspectives of development of anticancer vaccines with the use of dendritic cells of humans. Immunologiya 2002; 23: 8-15 (in Russian).
8. Cann SAH, van Netten J, van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 2003; 79: 672-80.
9. Fudenberg H, Whitten H. Immunostimulation: synthetic and biological modulators of immunity. Ann Rev Pharmacol Toxicol 1984; 24: 147-74. (Pubitemid 14129534)
10. Werner G, Jolles P. Immunostimulating agents: what next? A review of their present and potential medical applications. Eur J Biochem 1996; 242: 1-19. (Pubitemid 26386349)
11. O'Neill L, Bowie A. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7: 353-64. (Pubitemid 46674493)
12. Medzhitov R, Preston-Hurlburt P, Janeway C. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-7. (Pubitemid 27334820)
13. Mansell A, Smith R, Doyle SL, et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 2006; 7: 148-55.
14. Miller R. Imiquimod stimulates innate and cell mediated immunity which controls virus infections and tumors. Int J Dermatol 2002; 41: 3-6.
15. Gambashidze K, Khorava P. Anti-tumor effects of polyvaccine of Staphylococcus-Proteus-Escherichia-Klebsiella and polychemotherapy. Georg Int J Sci Technol 2010; 2: 7-14.
16. Meipariani A. Obtaining bacteriophages and study of immunogenity of phage lysates of disentery, PhD Thesis, Tbilisi, 1963, 75 p (In Russian).
17. Gachechiladze K. The study of antigenic properties of saturated phage lysates of Schigella flexneri. PhD Thesis, the second Mechnikov Institute: Moscow, 1964; 54 p. (in Russian).
18. Chanishvili N. Immune response to phage therapy. In: "A literature Review of the Practical Application of Bacteriophage Research", Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi, Georgia, 2009: 107-112.
19. Adams N. Bacteriophages. Interscience Publishers, Inc., New York, 1959: 27-31.
20. Clokie M, Kropinski A. Bacteriophages. Methods and Protocols, 1: Isolation, Characterization and Interactions. Humana Press, 2009: 54-75.
21. Mdzinarishvili T, Mrevlishvili G, Khvedelidze M, et al. Pycnometric, viscometric and calorimetric studies of the process to release the double-stranded DNA from the Un bacteriophage. Biophysical Chemistry 2006; 124: 43-51. (Pubitemid 44550060)
22. Bradford M. "Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding", Anal Biochem 1976; 72: 248-54.